Study Condition(s): Gastroesophageal Junction Cancer (GEJ), Stomach Cancer

A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer

Study Alias: JVCU

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02314117 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The main purpose of this study is to evaluate the effectiveness of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach cancer.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

18+ years

Time Commitment

The duration of your participation will depend on the duration of your study treatment, your disease progression, and follow-up visits
  • Participant must have a confirmed diagnosis of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

  • Participant must not have received any prior first-line systemic therapy (however, prior adjuvant or neo-adjuvant therapy is permitted)

  • Participant must have adequate organ function

  • Participant must agree to provide a tumor tissue sample

  • Participant must not have adenocarcinoma of the esophagus

  • Participant must not have human epidermal growth factor receptor 2 (HER2) positive status

  • Participant must not be receiving long term therapy with nonsteroidal anti-inflammatory agents (NSAIDs), however aspirin use at doses up to 325 mg/day is permitted

  • Participant must not have uncontrolled high blood pressure prior to initiating study treatment

  • Female participant must not be pregnant or lactating

Where to Participate

135 locations are currently available of 140 planned
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.